Evidence map›Paper›PMID 36834957›Full record

ArticleInternational journal of molecular sciences2023

Seasonal Changes in Serum Metabolites in Multiple Sclerosis Relapse.

Ekaterina Martynova, Timur Khaibullin, Ilnur Salafutdinov, Maria Markelova, Alexander Laikov, Leonid Lopukhov, Rongzeng Liu, Kritika Sahay, Mehendi Goyal, Manoj Baranwal and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Ekaterina MartynovaInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.
Timur KhaibullinRepublican Clinical Neurological Center, Republic of Tatarstan, 420021 Kazan, Russia.
Ilnur SalafutdinovInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.ORCID 0000-0001-6988-0673
Maria MarkelovaInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.
Alexander LaikovInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.ORCID 0000-0002-4250-2645
Leonid LopukhovInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.ORCID 0000-0001-6688-8776
Rongzeng LiuDepartment of Immunology, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang 471003, China.ORCID 0000-0002-0518-6145
Kritika SahayDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala 147004, India.
Mehendi GoyalDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala 147004, India.
Manoj BaranwalDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala 147004, India.ORCID 0000-0002-6581-9346
Albert A RizvanovInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.ORCID 0000-0002-9427-5739
Svetlana KhaiboullinaInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.
Kazan Federal University · RUThapar Institute of Engineering & Technology · INHenan University of Science and Technology · CNKazan State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a debilitating chronic disease of unknown etiology. There are limited treatment options due to an incomplete understanding of disease pathology. The disease is shown to have seasonal exacerbation of clinical symptoms. The mechanisms of such seasonal worsening of symptoms remains unknown. In this study, we applied targeted metabolomics analysis of serum samples using LC-MC/MC to determine seasonal changes in metabolites throughout the four seasons. We also analyzed seasonal serum cytokine alterations in patients with relapsed MS. For the first time, we can demonstrate seasonal changes in various metabolites in MS compared to the control. More metabolites were affected in MS in the fall season followed by spring, while summer MS was characterized by the smallest number of affected metabolites. Ceramides were activated in all seasons, suggesting their central role in the disease pathogenesis. Substantial changes in glucose metabolite levels were found in MS, indicating a potential shift to glycolysis. An increased serum level of quinolinic acid was demonstrated in winter MS. Histidine pathways were affected, suggesting their role in relapse of MS in the spring and fall. We also found that spring and fall seasons had a higher number of overlapping metabolites affected in MS. This could be explained by patients having a relapse of symptoms during these two seasons.

Indexed as

Multiple SclerosisChronic DiseaseCytokinesHumansRecurrenceSeasonsCytokinesautoimmune diseasesmetabolitesmultiple sclerosisserum

Identifiers

PMID36834957
PMCPMC9959388
OpenAlexW4319985532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.